The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors
Top Cited Papers
- 1 August 2010
- journal article
- practice guideline
- Published by Wolters Kluwer Health in Pancreas
- Vol. 39 (6) , 775-783
- https://doi.org/10.1097/mpa.0b013e3181ebb4f0
Abstract
Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic paraganglia, respectively. Serious morbidity and mortality rates associated with these tumors are related to the potent effects of catecholamines on various organs, especially those of the cardiovascular system. Before any surgical procedure is done, preoperative blockade is necessary to protect the patient against significant release of catecholamines due to anesthesia and surgical manipulation of the tumor. Treatment options vary with the extent of the disease, with laparoscopic surgery being the preferred treatment for removal of primary tumors. Medullary thyroid cancer (MTC) is a malignancy of the thyroid C cells or parafollicular cells. Thyroid C cells elaborate a number of peptides and hormones, such as calcitonin, carcinoembryonic antigen, and chromogranin A. Some or all of these markers are elevated in patients with MTC and can be used to confirm the diagnosis as well as to follow patients longitudinally for recurrence. Medullary thyroid cancer consists of a spectrum of diseases that ranges from extremely indolent tumors that are stable for many years to aggressive types associated with a high mortality rate. Genetic testing for RET mutations has allowed identification of familial cases and prophylactic thyroidectomy for cure. The only curative treatment is complete surgical resection.Keywords
This publication has 77 references indexed in Scilit:
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Suberoyl Bishydroxamic Acid Activates Notch1 Signaling and Suppresses Tumor Progression in an Animal Model of Medullary Thyroid CarcinomaAnnals of Surgical Oncology, 2008
- Valproic Acid Activates Notch1 Signaling and Induces Apoptosis in Medullary Thyroid Cancer CellsAnnals of Surgery, 2008
- Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patientsEuropean Journal of Surgical Oncology, 2007
- Medullary thyroid cancer: therapeutic targets and molecular markersCurrent Opinion in Oncology, 2007
- Prognosis of medullary thyroid carcinomaCancer, 2006
- Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma SyndromesJournal of Clinical Endocrinology & Metabolism, 2006
- Hereditary medullary thyroid carcinoma in patients greater than 50 years oldSurgery, 2004
- Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancerSurgery, 1995